Freedom of Information request on reports for patients that had Iohexol admitted at Pinderfields, Pontefract and Dewsbury hospitals (FOI 21/481)
Published 28 June 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-24-may-2021/freedom-of-information-request-on-reports-for-patients-that-had-iohexol-admitted-at-pinderfields-pontefract-and-dewsbury-hospitals-foi-21481
25th May 2021 FOI 21/481
Dear
Thank you for your email dated 4th May 2021, where you requested the following:
Reports for patients that had Iohexol admitted at Pinderfields Hospital, Pontefract hospital and Dewsbury hospital, including patients home addresses with postcodes WF1 – WF17, from Jan 2020 – Jan 2021.
As per your request, from 01/01/2020 to 31/01/2021, I can confirm that we have received 11 Adverse Drug Reaction (ADR) reports associated with Omnipaque (Iohexol) from either Pinderfields hospital, Pontefract hospital or Dewsbury hospital. Please see attached tables where the information is presented in a line listing (Table 1), and aggregated patient age and sex (Tables 2-3).
The accuracy of the data relies on the extract postcodes for these hospitals being provided by the reporter on the original Yellow Card. Furthermore, if the postcode is incorrectly provided, the Yellow Card will not be included in this analysis. It is important to note any Yellow Card reports submitted where the reporter has only provided their email address will not be included. This information should only be used for education and promotion and not be used for audit purposes. Please note we cannot easily extract data for only home addresses within this area.
It is important to bear in mind the following points when interpreting Yellow Card data: • Please be aware, the reporting of a particular reaction does not necessarily mean that it has been caused by a drug or vaccine. Many factors must be considered in assessing the relationship between a drug or vaccine and suspected reaction including the possible contribution of other drugs being taken, and the underlying disease. • Furthermore, the number of reports received should not be used as a basis for determining incidence of a reaction as neither the total number of reactions occurring, nor the number of patients using a drug or vaccine is included in this data.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team, Vigilance and Risk Management of Medicines Division